Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 434

1.

CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer.

Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO.

Breast Cancer Res. 2012 Mar 15;14(2):R48.

2.
3.

Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, Earl HM, Poole CJ, Hiller L, Dunn JA, Bowden SJ, Twelves C, Bartlett JM, Mahmoud SM, Rakha E, Ellis IO, Liu S, Gao D, Nielsen TO, Pharoah PD, Caldas C.

Ann Oncol. 2014 Aug;25(8):1536-43. doi: 10.1093/annonc/mdu191. Epub 2014 Jun 9.

PMID:
24915873
4.

Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.

Cimino-Mathews A, Ye X, Meeker A, Argani P, Emens LA.

Hum Pathol. 2013 Oct;44(10):2055-63. doi: 10.1016/j.humpath.2013.03.010. Epub 2013 May 21.

5.

Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.

Blok EJ, van den Bulk J, Dekker-Ensink NG, Derr R, Kanters C, Bastiaannet E, Kroep JR, van de Velde CJ, Kuppen PJ.

Oncotarget. 2017 Feb 28;8(9):15610-15620. doi: 10.18632/oncotarget.14779.

6.

Intratumoral CD8⁺ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer.

Chen Z, Chen X, Zhou E, Chen G, Qian K, Wu X, Miao X, Tang Z.

PLoS One. 2014 Apr 17;9(4):e95475. doi: 10.1371/journal.pone.0095475. eCollection 2014.

7.

Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.

Park IH, Kong SY, Ro JY, Kwon Y, Kang JH, Mo HJ, Jung SY, Lee S, Lee KS, Kang HS, Lee E, Joo J, Ro J.

Clin Breast Cancer. 2016 Feb;16(1):51-8. doi: 10.1016/j.clbc.2015.07.006. Epub 2015 Aug 6.

PMID:
26364145
8.

[Prognostic value of T lymphocytes infiltration in breast cancer].

Yu HM, Jiao SC, Yang JL, Wang JD.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2013 Apr;35(2):199-206. doi: 10.3881/j.issn.1000-503X.2013.02.013. Chinese.

9.

Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR.

J Clin Oncol. 2011 May 20;29(15):1949-55. doi: 10.1200/JCO.2010.30.5037. Epub 2011 Apr 11.

PMID:
21483002
10.

Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study.

Ray PS, Bagaria SP, Wang J, Shamonki JM, Ye X, Sim MS, Steen S, Qu Y, Cui X, Giuliano AE.

Ann Surg Oncol. 2011 Dec;18(13):3839-47. doi: 10.1245/s10434-011-1657-8. Epub 2011 Mar 18.

PMID:
21424368
11.

Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival.

Paulson KG, Iyer JG, Tegeder AR, Thibodeau R, Schelter J, Koba S, Schrama D, Simonson WT, Lemos BD, Byrd DR, Koelle DM, Galloway DA, Leonard JH, Madeleine MM, Argenyi ZB, Disis ML, Becker JC, Cleary MA, Nghiem P.

J Clin Oncol. 2011 Apr 20;29(12):1539-46. doi: 10.1200/JCO.2010.30.6308. Epub 2011 Mar 21.

12.

Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.

Matsumoto H, Thike AA, Li H, Yeong J, Koo SL, Dent RA, Tan PH, Iqbal J.

Breast Cancer Res Treat. 2016 Apr;156(2):237-47. doi: 10.1007/s10549-016-3743-x. Epub 2016 Mar 9.

PMID:
26960711
13.

Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.

Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH.

Am J Clin Oncol. 2013 Jun;36(3):224-31. doi: 10.1097/COC.0b013e3182467d90.

PMID:
22495453
14.

Clinical significance of basal-like subtype in triple-negative breast cancer.

Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H.

Breast Cancer. 2009;16(4):260-7. doi: 10.1007/s12282-009-0150-8. Epub 2009 Aug 22.

PMID:
19701681
15.

Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients.

Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, Lardon F, Vermorken JB.

BMC Immunol. 2010 Apr 12;11:19. doi: 10.1186/1471-2172-11-19.

16.

Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes.

Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, Turashvili G, Gilks BC, Kennecke H.

Breast Cancer Res Treat. 2012 Feb;132(1):131-42. doi: 10.1007/s10549-011-1529-8. Epub 2011 May 15.

PMID:
21574055
17.

Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade.

Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, Foulkes WD.

Histopathology. 2011 Jun;58(7):1107-16. doi: 10.1111/j.1365-2559.2011.03846.x. Epub 2011 Jun 24.

PMID:
21707712
18.

Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer.

Ohi Y, Umekita Y, Yoshioka T, Souda M, Rai Y, Sagara Y, Sagara Y, Sagara Y, Tanimoto A.

Histopathology. 2011 Oct;59(4):776-80. doi: 10.1111/j.1365-2559.2011.03884.x.

PMID:
22014057
19.

The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.

Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, Kazkaz GA.

Breast Cancer Res Treat. 2014 Dec;148(3):467-76. doi: 10.1007/s10549-014-3185-2. Epub 2014 Nov 1. Review.

PMID:
25361613
20.

Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer.

Li J, Liu X, Tong Z.

Jpn J Clin Oncol. 2012 Jun;42(6):471-6. doi: 10.1093/jjco/hys046. Epub 2012 Apr 3.

PMID:
22493058

Supplemental Content

Support Center